Sign in
4

Changes in Ownership

Axsome Therapeutics, Inc. Filed Acc 0001193125-25-205260

Chief Executive Officer sold 62,880 shares at an average $117.08 ($7,361,891)

  • Chief Executive Officer acquired 62,880 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
TABUTEAU HERRIOT Chief Executive Officer 2025-09-12 Option exercise 10b5-1 +27,907 $8.02 $223,814 35,136 D: show line 1 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-09-12 Sale 10b5-1 −27,907 $118.96 $3,319,817 7,229 D: show line 2 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-09-15 Option exercise 10b5-1 +15,254 $8.02 $122,337 22,483 D: show line 3 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-09-15 Sale 10b5-1 −15,254 $117.37 $1,790,362 7,229 D: show line 4 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-09-16 Option exercise 10b5-1 +19,719 $8.02 $158,146 26,948 D: show line 5 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-09-16 Sale 10b5-1 −19,719 $114.19 $2,251,713 7,229 D: show line 6 in the form
Open-market sales · 62,880 sh · avg $117.08 · $7,361,891

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
TABUTEAU HERRIOT Chief Executive Officer 2025-09-12 Option exercise · Stock Option (Right to Buy) 10b5-1 −27,907 496,093 D: show line 7 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-09-15 Option exercise · Stock Option (Right to Buy) 10b5-1 −15,254 480,839 D: show line 8 in the form
TABUTEAU HERRIOT Chief Executive Officer 2025-09-16 Option exercise · Stock Option (Right to Buy) 10b5-1 −19,719 461,120 D: show line 9 in the form
Loading xslF345X05/ownership.xml…